利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

112 条记录 (耗时 0.167 秒)

    SYSTEM AND METHOD FOR OUTCOME TRACKING AND ANALYSIS
    72.
    发明申请
    SYSTEM AND METHOD FOR OUTCOME TRACKING AND ANALYSIS 有权

    公开(公告)号：US20220399131A1

    公开(公告)日：2022-12-15

    申请号：US17885412

    申请日：2022-08-10

    申请人： Foundation Medicine, Inc.

    发明人： Michael PELLINI ,  Gary PALMER ,  Mary Patricia LANCELOTTA ,  Matthew J. HAWRYLUK ,  Vincent A. MILLER

    IPC分类号： G16H70/60 ,  G16B30/00 ,  G16H15/00 ,  G16H10/60 ,  G16H10/20 ,  G16H50/20 ,  G16H20/10

    摘要： Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

    Therapeutic and diagnostic methods for cancer
    76.
    发明授权
    Therapeutic and diagnostic methods for cancer 有权

    公开(公告)号：US11300570B2

    公开(公告)日：2022-04-12

    申请号：US16371589

    申请日：2019-04-01

    申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

    发明人： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

    IPC分类号： G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

    摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).